We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker.  KRAS mutations were detected in the plasma of 66 patients (30%), and every mutation found in the plasma was identical to that subsequently found in the patient's primary tumor (100% concordance).  The use of KRAS in conjunction with four thresholded protein biomarkers increased the sensitivity to 64%. 
KRAS
We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker.  KRAS mutations were detected in the plasma of 66 patients (30%), and every mutation found in the plasma was identical to that subsequently found in the patient's primary tumor (100% concordance).  The use of KRAS in conjunction with four thresholded protein biomarkers increased the sensitivity to 64%. 
KRAS
We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker.  KRAS mutations were detected in the plasma of 66 patients (30%), and every mutation found in the plasma was identical to that subsequently found in the patient's primary tumor (100% concordance).  The use of KRAS in conjunction with four thresholded protein biomarkers increased the sensitivity to 64%. 
KRAS
We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker.  KRAS mutations were detected in the plasma of 66 patients (30%), and every mutation found in the plasma was identical to that subsequently found in the patient's primary tumor (100% concordance).  The use of KRAS in conjunction with four thresholded protein biomarkers increased the sensitivity to 64%. 
KRAS